MX2022007438A - Combinacion de inhibidores de ahr. - Google Patents

Combinacion de inhibidores de ahr.

Info

Publication number
MX2022007438A
MX2022007438A MX2022007438A MX2022007438A MX2022007438A MX 2022007438 A MX2022007438 A MX 2022007438A MX 2022007438 A MX2022007438 A MX 2022007438A MX 2022007438 A MX2022007438 A MX 2022007438A MX 2022007438 A MX2022007438 A MX 2022007438A
Authority
MX
Mexico
Prior art keywords
component
inhibitor
treatment
combinations
ahr
Prior art date
Application number
MX2022007438A
Other languages
English (en)
Inventor
Ilona Gutcher
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of MX2022007438A publication Critical patent/MX2022007438A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

La presente invención se refiere a combinaciones de al menos dos componentes, componente A y componente B, siendo el componente A un inhibidor de AhR y siendo el componente B pembrolizumab o nivolumab. Otro aspecto de la presente invención se refiere a combinaciones de tres componentes, componente A, componente B y componente C; el componente A es un inhibidor de AhR, el componente B es pembrolizumab o nivolumab y el componente C es otro agente farmacéutico. La presente invención se refiere además al uso de combinaciones como las descritas aquí para la preparación de un medicamento para el tratamiento o profilaxis de una enfermedad, particularmente para el tratamiento o profilaxis de cánceres de mama, vías respiratorias, cerebro, órganos reproductivos, digestivo tracto urinario, ojo, hígado, piel, riñón, cabeza y cuello, tiroides, paratiroides y sus metástasis a distancia, linfomas, sarcomas y leucemias.
MX2022007438A 2019-12-16 2020-12-14 Combinacion de inhibidores de ahr. MX2022007438A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962948430P 2019-12-16 2019-12-16
EP19216672 2019-12-16
PCT/EP2020/085938 WO2021122434A1 (en) 2019-12-16 2020-12-14 Combination of an ahr-inhibitor and an pd1-inhibitor antibody and its use in the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2022007438A true MX2022007438A (es) 2022-07-19

Family

ID=73790120

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007438A MX2022007438A (es) 2019-12-16 2020-12-14 Combinacion de inhibidores de ahr.

Country Status (11)

Country Link
US (1) US20230084899A1 (es)
EP (1) EP4076462A1 (es)
JP (1) JP2023505907A (es)
KR (1) KR20220128622A (es)
CN (1) CN114786674A (es)
AU (1) AU2020403801A1 (es)
BR (1) BR112022007837A2 (es)
CA (1) CA3164474A1 (es)
IL (1) IL293861A (es)
MX (1) MX2022007438A (es)
WO (1) WO2021122434A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114835687B (zh) * 2021-04-02 2023-09-05 北京华森英诺生物科技有限公司 AhR抑制剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
CA2970873C (en) 2005-05-09 2022-05-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
EP3222634A1 (en) 2007-06-18 2017-09-27 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
CN105461687B (zh) * 2014-08-26 2020-06-19 北京京奉医药科技有限公司 含二氢哒嗪酮的喹啉类化合物及其用途
MX2018014443A (es) * 2016-05-25 2019-04-15 Bayer Pharma AG 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas.
JOP20190193A1 (ar) 2017-02-09 2019-08-08 Bayer Pharma AG ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان
WO2019101643A1 (en) * 2017-11-21 2019-05-31 Bayer Aktiengesellschaft 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides
US11459312B2 (en) * 2017-11-21 2022-10-04 Bayer Aktiengesellschaft Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides

Also Published As

Publication number Publication date
IL293861A (en) 2022-08-01
JP2023505907A (ja) 2023-02-13
EP4076462A1 (en) 2022-10-26
CA3164474A1 (en) 2021-06-24
US20230084899A1 (en) 2023-03-16
CN114786674A (zh) 2022-07-22
KR20220128622A (ko) 2022-09-21
WO2021122434A1 (en) 2021-06-24
AU2020403801A1 (en) 2022-06-02
BR112022007837A2 (pt) 2022-07-05

Similar Documents

Publication Publication Date Title
BR112021009595A2 (pt) Terapia de combinação incluindo um inibidor de krasg12c e um ou mais agentes farmaceuticamente ativos adicionais para o tratamento de cânceres
WO2018033254A3 (en) Rna for cancer therapy
MX2021004110A (es) Composiciones farmaceuticas que comprenden n-(3,5- dimetoxifenil)-n'-(1-metiletil)-n-[3-(1-metil-1h- pirazol-4-il)quinoxalin-6-il]etano-1,2-diamina.
MX2019007156A (es) Inhibidores de imidazopirazina de la tirosina cinasa de bruton.
CR20200334A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
EP4241850A3 (en) Mdm2 inhibitors and combinations thereof
MX2019012884A (es) Terapia de combinacion.
NZ767296A (en) Liquid inhalation formulation comprising rpl554
CR20210532A (es) Protacs que degradan el receptor de estrógeno
ZA201907225B (en) Treatment of her2 positive cancers
MX2016011667A (es) Composiciones topicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad.
MX2023003564A (es) Compuestos y su uso en el tratamiento del cancer.
MX2018005715A (es) Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash.
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
MX2022007438A (es) Combinacion de inhibidores de ahr.
MX2018008078A (es) Tecnologia de sinergismo anticuerpo-farmaco para el tratamiento de enfermedades.
MX2020001253A (es) Combinacion terapeutica de un inhibidor tirosina quinasa del egfr de tercera generacion y un inhibidor de quinasa dependiente de ciclina.
SI3030554T1 (en) PIPERIDIN-SEA DERIVATIVES
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
JOP20200014A1 (ar) توليفة علاجية لمثبط كيناز تيروزين egfr من الجيل الثالث ومثبط raf
IL250852B (en) Periodontal preparation
MY194488A (en) Syd985 treatment of t-dm1 refractory cancer patients
MX2022002185A (es) Composicion farmaceutica acuosa de anticuerpo anti-pd1 prolgolimab y su uso.
ZA202104321B (en) Aqueous paediatric retinol formulations